Cargando…

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition

Ibrutinib (Imbruvica; PCI-32765) is an orally administered inhibitor of Bruton's tyrosine kinase that has transformed the treatment of B-cell malignancies. However, ibrutinib has very low oral bioavailability that contributes to significant variability in systemic exposure between patients, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eisenmann, Eric D., Fu, Qiang, Muhowski, Elizabeth M., Jin, Yan, Uddin, Muhammad Erfan, Garrison, Dominique A., Weber, Robert H., Woyach, Jennifer A., Byrd, John C., Sparreboom, Alex, Baker, Sharyn D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691714/ https://www.ncbi.nlm.nih.gov/pubmed/34950932 http://dx.doi.org/10.1158/2767-9764.CRC-21-0076

Ejemplares similares

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
por: Garrison, Dominique A., et al.
Publicado: (2022)

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
por: Garrison, Dominique A., et al.
Publicado: (2020)

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1
por: Uddin, Muhammad Erfan, et al.
Publicado: (2021)

Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method
por: Talebi, Zahra, et al.
Publicado: (2023)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
por: Anderson, Jason T., et al.
Publicado: (2019)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
por: Chen, Timothy L., et al.
Publicado: (2021)

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
por: de Jong, Jan, et al.
Publicado: (2015)

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
por: Guinn, Daphne, et al.
Publicado: (2014)

Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants
por: de Jong, Jan, et al.
Publicado: (2015)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
por: Muhowski, Elizabeth M., et al.
Publicado: (2022)

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
por: Woyach, Jennifer A., et al.
Publicado: (2023)

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities
por: Li, Yang, et al.
Publicado: (2022)

Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6
por: de Jong, Jan, et al.
Publicado: (2020)

Formation of CYP3A‐specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β‐hydroxycholesterol/cholesterol ratio
por: Lee, Jonghwa, et al.
Publicado: (2022)

Predicting Paclitaxel Disposition in Humans With Whole‐Body Physiologically‐Based Pharmacokinetic Modeling
por: Fu, Qiang, et al.
Publicado: (2019)

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib
por: Nyga, Rémy, et al.
Publicado: (2019)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors
por: Uddin, Muhammad Erfan, et al.
Publicado: (2021)

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
por: Ruppert, Amy S., et al.
Publicado: (2021)

MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia
por: Uddin, Muhammad Erfan, et al.
Publicado: (2022)

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100
por: Smith, N F, et al.
Publicado: (2008)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Arrhythmia Patterns in Patients on Ibrutinib
por: Fazal, Muhammad, et al.
Publicado: (2022)

TP-0903 is active in models of drug-resistant acute myeloid leukemia
por: Jeon, Jae Yoon, et al.
Publicado: (2020)

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
por: Woyach, Jennifer A., et al.
Publicado: (2023)

Ibrutinib‐induced severe liver injury
por: Nandikolla, Amara G., et al.
Publicado: (2017)

A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
por: Natarajan, Gayathri, et al.
Publicado: (2016)

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
por: Munir, Talha, et al.
Publicado: (2019)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma
por: Lindholm, Kaleigh E., et al.
Publicado: (2021)

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
por: Montillo, M, et al.
Publicado: (2017)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Deciphering the Electrophysiological Mechanisms for Ibrutinib-Induced Ventricular Arrhythmias
por: Kudinov, Alex, et al.
Publicado: (2020)

DNA methyltransferase inhibitor exposure–response: Challenges and opportunities
por: Kagan, Amanda B., et al.
Publicado: (2023)

Ibrutinib: Rebound effect in the form of respiratory deterioration following the discontinuation of ibrutinib: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4u4khtkn9dbdhnq9ssf4652enq